The distinguished ESMO Hamilton Fairley Award was established in 1998 to commemorate one of the founding fathers of medical oncology in Europeand is presented to candidates who are internationally recognised for lifetime achievements in cancer science and clinical / laboratory research.
This award is presented to candidates who are internationally recognised for lifetime achievements in cancer science and clinical / laboratory research.
Selection
Candidates for the award will be considered by the
ESMO Fellowship and Award Committee
of renowned cancer leaders. After careful deliberations by the committee, its recommendations will be forwarded to the ESMO Executive Board for final consideration and selection.
The choice of the award winner will be made on the basis of the candidate's scientific accomplishments. No regard will be given to race, gender, and nationality, religious or political views.
The award consists of a statuette and the opportunity to give a 20-minute lecture at either the ESMO or the ECC Congress, free registration, free accommodation and reimbursement of travel expenses.
The 2012 Hamilton Fairley Award winner Prof. Jean-Yves Blay, Centre Léon Bérard, Lyon, France:
It is an immense privilege to receive this award. The recognition by ESMO, an organisation I cherish particularly, is extremely important to me. Translational research has been my focus overall these years, with the ups and downs of all research activities. So this is a major encouragement to continue. Even more importantly, I am certain that this award will help me to convince the young medical researchers - the next generation to focus on applied research. This is happening here and now.
Awardees of the Hamilton Fairley award
2012 ESMO Vienna - Jean-Yves Blay, France
The recipient of the 2012 Hamilton Fairley Award is Professor Jean-Yves Blay, for his contribution to translational cancer research. Jean-Yves Blay is Professor of Medicine in Medical Oncology and Head of the Medical Oncology Department and the Translational Research Pole at the Centre Léon Bérard of the Université Claude Bernard in Lyon, France. He is one of Europe’s most published lead and co-authors, with more than 350 peer-reviewed papers, principally on sarcomas, GIST and immunotherapy. He writes and lectures on public health issues such as breast and prostate cancer screening programmes. He is a president of the EORTC and serves as scientific committee member of 5 cancer centres in France. He has been a reviewer for the Journal of Clinical Oncology, Blood, Cancer, Annals of Oncology, and the European Journal of Cancer.
2011 EMCC Stockholm - Rafael Rosell, Spain
The Hamilton Fairley Award will be given to Professor Rosell, a leading figure in the field of lung cancer for many years. He established a very productive group of clinical and laboratory investigators in the Medical Oncology Department at Hospital Trias i Pujol, which has grown and became one of the leading centres in lung cancer management. Prof. Rosell is the founder and the scientific leader of the Spanish Lung Cancer Group (SCLG), that has made major contributions impacting the treatment of lung cancer and the direction of future developments aiming to provide the best therapeutic options based on molecular tumour characteristics. Prof. Rosell has been the principal investigator in a number of clinical trials, he has demonstrated long-term commitment to clinical and translational research in the lung cancer field. Prof. Rosell’s contributions range from tumour biology to prognostic and treatment-predictive markers, clinical trials involving chemotherapy and targeted agents with careful dedication to personalised medicine.
2010 ESMO Milan - Bengt Glimelius, Sweden
The Hamilton Fairley Award will be given to Prof. Glimelius, a leading figure in the field of gastrointestinal oncology. Prof. Glimelius has been principal investigator in a number of clinical trials, a mentor for a new generation of surgeons, oncologists, and pathologists and is currently Editor-in-Chief for Acta Oncologica. He has educated and inspired health care personnel and scientists and improved the outlook for cancer patients. He has demonstrated long-term commitment to clinical and translational research, particularly within gastrointestinal cancer and malignant lymphoma, which has refined treatment and improved prognosis. Prof. Glimelius' contributions range from epidemiology and tumour biology to prognostic and treatment-predictive markers, clinical trials involving chemotherapy and optimised radiation therapy with careful analyses of late effects from cancer and its treatments.
